公开(公告)号：EP1516866B1

公开(公告)日：2006-07-12

申请号：EP03712147.2

申请日：2003-04-03

Applicant: PULEVA BIOTECH, S.A.

Inventor： GEERLINGS, Arjan ,  LOPEZ-HUERTAS Leon, Eduardo ,  MORALES SANCHEZ, Juan Carlos ,  BOZA PUERTA, Julio ,  JIMENEZ LOPEZ, Jesus

IPC: C07C69/025 ,  C07C69/16 ,  A61K31/222 ,  A61Q17/04 ,  A61P9/00 ,  A61P1/16 ,  A61P13/00 ,  A61P3/10 ,  A61P29/00

CPC classification number: A23C9/13 ,  A23C9/152 ,  A23C15/12 ,  A23L33/105 ,  A23V2002/00 ,  A23V2250/2131 ,  A61K8/37 ,  A61Q17/04 ,  C07C69/007 ,  C07C69/017 ,  C07C69/28 ,  C07C69/30 ,  C07C69/533 ,  C07C69/58 ,  C07C69/587 ,  A23V2200/326 ,  A23V2250/2132

Abstract: The invention relates to phenolic compounds and the derivatives thereof which are represented by formula I, wherein: R1 and R2 are selected from OH, OCOalkyl or OCOalkenyl; R3 is H, OH, OCOalkyl or OCOalkenyl; the alkyl or alkenyl chains have between 2 and 22 carbon atoms; and at least one OCOalkyl or OCOalkenyl group is present in the structure. More specifically, the invention relates to the use of said compounds for the prevention or treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications. The invention also relates to compositions containing the above-mentioned compounds and to some novel phenolic compounds and the derivatives thereof.

公开(公告)号：EP1609783A1

公开(公告)日：2005-12-28

申请号：EP04076731.1

申请日：2004-06-17

Applicant: Neuropharma S.A.U.

Inventor： Martinez Gil, Ana ,  Alonso Gordillo, Diana ,  Dorronsoro Diaz, Isabel ,  Garcia Palomero, Esther ,  de Austria de Luque, Celia ,  Usan Egea, Paola ,  del Monte Millan, Maria ,  Median Padilla, Miguel

IPC: C07D261/20 ,  A61K31/42

CPC classification number: C07D261/20

Abstract: The invention provides compounds having two spiro heterocyclic units connected through a linker of a certain length. Some of these compounds have been obtained from Aplysinia sp. The compounds exhibit VDCC blocker activity as well as acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of use in the treatment of brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jacob disease or Gerstmann-Straussler-Scheinher disease.

Abstract translation: 本发明提供具有通过一定长度的接头连接的两个螺杂环单元的化合物。 这些化合物中的一些已经从Aplysinia sp。 该化合物显示VDCC阻断活性以及乙酰胆碱酯酶和丁酰胆碱酯酶抑制活性。 因此，它们可用于治疗用于治疗脑缺血，中风，认知障碍如老年痴呆，脑血管性痴呆，轻度识别损伤，注意力缺陷障碍和/或异常蛋白质聚集的神经变性性痴呆疾病，特别是阿尔茨海默病或 条件或朊病毒疾病，如克雅氏弧菌病或Gerstmann-Straussler-Scheinher病。

公开(公告)号：EP1595865A1

公开(公告)日：2005-11-16

申请号：EP04380104.2

申请日：2004-05-10

Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.

Inventor： Noheda Marin, Pedro, Inst. de Quimica Organica Gen ,  Bernabe Pajares, M., Inst. de Quimica Organica Gen ,  Maroto Quintana, S., Inst. de Quimica Organica Gen ,  Tabares Cantero, N., Inst. de Quimica Organica Gen

IPC: C07D205/12

CPC classification number: C07D205/12

Abstract: New spirolactams of formula (I) having a benzodienone moiety and a azetidinone moiety which are highly stable due to pi interactions. They are useful as UV absorbers and as synthetic intermediates.

Abstract translation: 具有苯并二烯酮部分和由于π相互作用而高度稳定的氮杂环丁酮部分的新的式（I）的聚己内酰胺。 它们可用作紫外线吸收剂和合成中间体。

公开(公告)号：EP1586318A1

公开(公告)日：2005-10-19

申请号：EP04075997.9

申请日：2004-04-05

Applicant: Neuropharma S.A.U.

Inventor： Martinez Gil, Ana ,  Dorronsoro Diaz, Isabel ,  Alonso Cascon, Mercedes ,  Panizo del Priego, Gema ,  Fuertes Huerta, Ana ,  Perez Puerto, Maria José ,  Medina Padilla, Miguel

IPC: A61K31/433 ,  C07D285/08 ,  C07D417/04 ,  A61P25/28 ,  A61P3/10

CPC classification number: C07D285/08 ,  C07D417/04

Abstract: Provided are compounds of formula I wherein R 1 is an organic group having at least 8 atoms selected from C or O which is not linked directly to the N through a -C(O)- and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease and type II diabetes.

Abstract translation: 提供式I化合物，其中R 1是具有至少8个选自C或O的原子的有机基团，其不直接通过-C（O）与N直接相连，以及它们的药物组成。 这些化合物是选择性GSK-3抑制剂并具有改善的生物利用度。 它们可用于治疗GSK-3介导的疾病，其中包括阿尔茨海默病和II型糖尿病。

公开(公告)号：EP1508333B1

公开(公告)日：2006-05-24

申请号：EP03709839.9

申请日：2003-03-20

Applicant: Advanced in Vitro Cell Technologies, S.L.

Inventor： L PEZ BLANCO, José M., Centro de Patentes de la UB ,  CAMP S MOYA, Clara, Centro de Patentes de la UB ,  GIL SANTANO, Juan, Centro de Patentes de la UB

IPC: A61K31/7056 ,  A61P35/00

CPC classification number: A61K31/7056

Abstract: The invention relates to a novel therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine). Acadesine (also known as AICA riboside or AICAR) does not inhibit apoptosis in lymphocytes, as would be expected, but it does induce apoptosis in the B-cells of patients with B-type lymphoproliferative diseases, such as chronic B-cell (B-CLL) lymphatic leukaemia, splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL) and Waldenstrom's syndrome (WS). The T-cells are not affected. As a result, acadesine and the bioprecursors thereof (e.g. the mono, di- and tri-5'-phosphates thereof) are converted into therapeutic agents that can be used against lymphoproliferative diseases in humans. The surprising characteristic whereby the T-cells are barely affected means that the adverse secondary effect (immunosuppression) is slight, which represents a therapeutic advantage offered by acadesine over cladribine, fludarabine and other nucleosides known in the art.

公开(公告)号：EP1655317A1

公开(公告)日：2006-05-10

申请号：EP04078079.3

申请日：2004-11-09

Applicant: Ipagsa Industrial, SL.

Inventor： Bentley, Peter Jonathan

IPC: C08G8/28 ,  B41C1/10 ,  G03F7/00

CPC classification number: B41C1/1008 ,  B41C2210/02 ,  B41C2210/06 ,  B41C2210/22 ,  B41C2210/262 ,  B41M5/368 ,  C09B69/105

Abstract: The invention provides a near infrared absorption polymer comprising at least two different pendent infra-red chromophoric moieties covalently bonded to the backbone of an alkali-soluble resin, at least one of which is an indole cyanine dye and the other of which is a benz [e]-indole cyanine dye. When used in the coating of a heat sensitive positive working lithographic printing plate precursor the stabilization time needed after manufacture is significantly reduced, avoiding further conditioning processes before use. The precursors are preferably imagewise exposed with a near-infrared laser emitting at between 780 nm and 850 nm.

Abstract translation: 本发明提供一种近红外线吸收聚合物，其包含至少两种不同的悬挂的红外发色部分共价键合的碱溶性树脂的主链中，至少所有这是吲哚花青染料和其他的所有其是苯并〔一个 E]吲哚花青染料。 当在热的涂层中使用敏感正型平版印刷版原版制造被显着降低之后所需要的稳定时间，在使用前避免进一步的调理过程。 该前体优选成像用近红外激光在780nm处和850纳米之间发射露出。

公开(公告)号：EP1630159A1

公开(公告)日：2006-03-01

申请号：EP04380172.9

申请日：2004-08-18

Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.

Inventor： Torrens Jover, Antoni Lab. del Dr. Esteve R&D ,  Mas Prio, Josep Lab. del Dr. Esteve R&D ,  Yenes Minguez, Susana Lab. del Dr. Esteve R&D ,  Garcia Lopez, Monica Lab. del Dr. Esteve R&D ,  Dordal Zueras, Alberto Lab. del Dr. Esteve R&D ,  Romero Alonso, Luz Lab. del Dr. Esteve R&D ,  Buschmann, Helmut H. Lab. del Dr. Esteve R&D

IPC: C07D217/04 ,  C07D409/12 ,  C07D413/14 ,  C07D401/12 ,  C07D513/04 ,  C07D413/12 ,  C07D417/12 ,  A61K31/47 ,  A61K31/4725 ,  A61P25/00

CPC classification number: C07D513/04 ,  C07D217/04 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The invention relates to compounds of formula (I):

having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline propyl sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

Abstract translation: 本发明涉及式（I）化合物：具有针对5-HT 7受体的药理学活性，更具体地说，涉及一些四氢异喹啉丙磺酰胺化合物，其制备方法，包括它们的药物组合物，以及其用于 治疗和/或预防其中涉及5-HT的疾病，例如CNS障碍。

公开(公告)号：EP1598336A1

公开(公告)日：2005-11-23

申请号：EP04076477.1

申请日：2004-05-20

Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.

Inventor： Noheda Marin, Pedro, Instituto de Quimica Org. Gen ,  Bernabé Pajares, Manuel, Inst. de Quimica Org. Gen ,  Maroto Quintana, Sergio, Inst. de Quimica Org. Gen ,  Tabares Cantero, Nuria, Inst. de Quimica Org. Gen

IPC: C07D205/12

CPC classification number: C07D491/10 ,  C07D205/12 ,  C07F7/186

Abstract: The invention provides highly functionalised spiro-fused azetidinones of formula (I) having a cyclohexane moiety with the desired number of protected or unprotected hydroxyl groups which are introduced with high stereo and regioselectivity, as well as processes for their obtention.

Abstract translation: 本发明提供式（I）的具有所需数目的保护或未保护的羟基的环己烷部分的具有高立体和区域选择性的高官能度的螺 - 稠合氮杂环丁酮以及它们的获得方法。

公开(公告)号：EP1462466B1

公开(公告)日：2005-07-27

申请号：EP01994847.0

申请日：2001-12-31

Applicant: Acideka, S.A.

Inventor： OCHOA GOMEZ, José Ramón ,  SASIA SANTOS, Pedro Manuel ,  DIAZ DE APODACA, Elena ,  GOMEZ ALIENDE, Nicomedes ,  VALLE CHAUSSON, Beatriz Fundacion Leia, C.D.T. ,  RIO PEREZ, Francisca Fundacion Leia, C.D.T. ,  ESCUDERO SANZ, Javier

IPC: C08F220/56 ,  C08F2/32 ,  B01F17/00

CPC classification number: B01F17/00 ,  C08F2/32 ,  C08F220/56

Abstract: The invention relates to a method of producing reverse microemulsions from cationic copolymers. The inventive method consists in the polymerisation of a non-ionic monomer and a cationic monomer into a reverse microemulsion. Said polymerisation is carried out in the presence of an auto-reversible surfactant system in contact with an aqueous suspension or solution which can thermodynamically stabilise the system. According to the invention, the non-ionic monomer/cationic monomer mass ratio is included between 99:1 and 20:80.

公开(公告)号：EP1550873A1

公开(公告)日：2005-07-06

申请号：EP03380310.7

申请日：2003-12-30

Applicant: Progenika Biopharma, S.A. ,  UNIVERSIDAD DEL PAIS VASCO

Inventor： Ariz Lopez de Castro, Usue ,  Osaba Ortiz de Mendibil, Lourdes ,  Junquera Sanchez-Vallejo, Corina ,  Ochoa Garay, Jorge ,  Escuredo Garcia de Galdeano, Pedro ,  Santa Cruz, Simon ,  Simon Buela, Laureano ,  Martinez Martinez, Antonio ,  MatuteAlmau, Carlos ,  Domercq Garcia, Maria ,  Alberdi Alfonso, Elena ,  Victoria Sanchez Gomez, Maria ,  Vallejo Illarramendi, Ainara(2) ,  Ibarretxe Bilbao, Gaskon (2) ,  Etxebarria Galnares, Estibaliz (2)

IPC: G01N33/573 ,  C12N9/16

CPC classification number: C12N9/16 ,  C12Q1/42 ,  G01N33/5088 ,  G01N33/564 ,  G01N2800/285

Abstract: The present invention refers to an in vitro method for detecting the presence of demyelinating diseases in an individual, for determining the stage or severity of said diseases in the individual, or for monitoring the effect of the therapy administered to an individual suffering said diseases; to the search, identification, development and evaluation of efficacy of compounds for therapy of said diseases for the purpose of developing new drugs; as well as to agents inhibiting DUSP6 protein expression and/or activity, and/or the effects of this expression. The methods and agents of the invention are preferably applied to multiple sclerosis.

Abstract translation: 本发明涉及体外方法，用于检测在对个别脱髓鞘疾病的存在，用于确定性开采阶段或所述疾病在个体的严重程度，或用于监测施用于个体患有所述疾病的治疗的效果; 到所述疾病为开发新药的目的的治疗搜索，鉴定，开发和评估化合物的功效的; 以及到代理抑制DUSP6蛋白表达和/或活性，和/或该表达的影响。 本发明的方法和试剂，优选适用于多发性硬化症。